TOP10 ophthalmic drugs exposed!

The enthusiasm for the ophthalmology gold track continues to heat up, and another eye drop from Yangzijiang Pharmaceutical has been approved for marketing
.
The latest data shows that the sales of terminal ophthalmic drugs in public medical institutions in China in 2021H1 exceeded 5 billion yuan, a year-on-year increase of 29.

The eye drops that soared by 109.
22%, Yangzijiang won

On October 28, the official website of NMPA showed that Yangzijiang Pharmaceutical Co.
, Ltd.
was approved to market with the imitation of moxifloxacin hydrochloride eye drops for production in Category 4, and the approval number was H20213835
.

Moxifloxacin is the fourth-generation quinolone drug developed by Novartis.
On the basis of retaining the broad-spectrum antibacterial activity, antibacterial efficacy and safety advantages of quinolone, it is significantly stronger than the most widely used clinically levofloxacin eye drops (third-generation quinolone) It has the activity against Gram-positive bacteria, anaerobic bacteria and drug-resistant bacteria
.

Novartis' moxifloxacin hydrochloride eye drops were approved for import in China in 2018, and the domestic market is still in the development stage
.
According to data from Menet.

Sales of terminal moxifloxacin eye drops in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

Moxifloxacin hydrochloride eye drops have been included in the fifth batch of centralized procurement
.
Up to now, moxifloxacin hydrochloride ophthalmic solution over commentary enterprises has reached seven, including Qilu Pharmaceutical, Qi Xing eyedrops, Cologne medicine and so on

Golden track! The ophthalmic medicine market soars by 30%

Ophthalmology medicine has a broad market space and high technical barriers, and it is recognized as a golden track
.
According to the latest data from Mi Nei.

Sales of terminal ophthalmic drugs in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

From the perspective of the manufacturer's structure, Novartis, Kanghong Pharmaceutical, and Santian Pharmaceutical have been ranked TOP3 for many consecutive years.
Novartis's market share in 2021H1 exceeded 20%.
Kanghong Pharmaceutical's market share has also continued to rise.
It has now surpassed Santian Pharmaceutical and has been promoted to second place
.

In the sub-categories of ophthalmic drugs, ocular vascular disease treatment drugs, other ophthalmic drugs, and anti-infective drugs are among the top three
.
Among them, the sales of ocular vascular disease treatment drugs are close to 2 billion yuan, and the sales of other ophthalmic drugs are close to 1.

With the aging of the population in China, the number of patients with age-related eye diseases continues to increase; the eye health of adolescents is getting worse and the myopia rate ranks first in the world; For problems such as ophthalmopathy, the demand for ophthalmology has great potential, and the market will also rise
.

TOP10 ophthalmic drugs are released! Kang Hong and Shangyao are on the list

Among the TOP10 ophthalmic products, 10 products have sales of over 100 million yuan, and 4 are exclusive products
.
The sales of TOP3 products ranibizumab injection, conbercept ophthalmic injection and sodium hyaluronate eye drops all exceeded 500 million yuan

Except for the sales of levofloxacin eye drops included in the third batch of centralized procurement, the sales of the other 9 products showed substantial growth.
The sales of aflibercept intraocular injection solution increased by more than 140%, and the sales of polyvinyl alcohol eye drops Sales increased by more than 60%
.

2021H1 China's top 10 public medical institutions' terminal ophthalmic drug products

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

Among the TOP10 ophthalmic drug brands, foreign brands such as Novartis, Santen Pharmaceuticals, and URSAPHARM account for more than half of the seats.
Domestic brands on the list include Kanghong Pharmaceutical’s Conbercept ophthalmic injection, Shanghai Pharmaceutical First Biochemical’s injection chymotrypsin, and Xin Dongsheng Technology’s polyvinyl alcohol eye drops and Shandong Haishan Pharmaceutical’s Pranoprofen eye drops
.

2021H1 Top 10 Brands of Terminal Ophthalmology Drugs in Public Medical Institutions in China

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

9 varieties have been reviewed! Xingqi, Qilu, and Yangtze River "Strong Attack" Eye Drops

Since the beginning of this year, there have been 6 varieties of ophthalmic drugs approved for marketing in China (involving 14 product regulations)
.
Except for Yuanda Tiantian’s Bimeprost eye drops which was approved for imitation of 6 categories, all other products were approved under the new registration classification and deemed to have passed the consistency evaluation

Ophthalmic drugs approved for marketing since 2021

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Up to now, 9 types of ophthalmic drugs (involving 27 product regulations) have been reviewed, all of which have been reviewed in the new registration classification method
.
Among them, moxifloxacin hydrochloride eye drops and levofloxacin eye drops have been reviewed by 6 companies, cyclosporine eye drops (Ⅱ), brimonidine tartrate eye drops, sodium chloride eye drops, travo There is only one company that has been reviewed for 4 varieties including Prostaglandin Eye Drops

Consistency evaluation of ophthalmic medications passed/deemed passed

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Among the 9 over-reviewed eye drops, levofloxacin eye drops, olopatadine hydrochloride eye drops, sodium hyaluronate eye drops, and moxifloxacin hydrochloride eye drops have been included in the third, fourth, and fifth batches of centralized procurement, respectively
.
Yangzijiang Pharmaceutical and Zhongshan Wanhan Pharmaceutical each have 2 varieties selected
.

Selection of National Centralized Ophthalmology Drugs

In addition, bromfenac sodium eye drops have also met centralized procurement, and it is expected to be included in national centralized procurement in the future
.
According to data from Meinenet, the domestic market for bromfenac sodium eye drops continues to rise.
In 2020, the terminal sales of public medical institutions in China will exceed 100 million yuan, and the sales will increase by 33.
85% in the first half of 2021
.

From the perspective of reviewing companies, Xingqi Eyedrops and Yangzijiang Pharmaceuticals each have 3 varieties reviewed, and Qilu Pharmaceuticals, Chengdu Push Pharmaceuticals, Zhongshan Wanhan Pharmaceuticals and other 4 companies have reviewed 2 varieties
.
It is worth noting that Xingqi Eyedrops, Qilu Pharmaceutical, Zhongshan Wanhan Pharmaceutical and many other eye drops products are still under review
.